Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-12-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
协和干细胞基因工程有限公司拟收购协和华东干细胞基因工程有限公司股权项目资产评估报告书
Regulatory Filings
2016-12-30 Chinese
关于子公司协和干细胞基因工程有限公司收购协和华东干细胞基因工程有限公司52.60%股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a transaction where a subsidiary company acquires a 52.60% equity stake in another company, including related party transactions, asset valuation, agreements, and approvals. It includes financial data, audit references, and detailed transaction terms. The content focuses on a capital acquisition and related party transaction, which is a financing and capital structure update rather than a full annual or interim report, earnings release, or management discussion. It is not a proxy, voting result, or board change announcement. The document length is substantial (9461 characters) and contains detailed transaction and financing information. Therefore, the document fits best under Capital/Financing Update (CAP).
2016-12-30 Chinese
第八届董事会第六十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the decisions made at the 64th meeting of the 8th board, including approval of a subsidiary's acquisition and the proposal to convene an extraordinary general meeting. The document includes voting results and references related announcements. It is not a full report but an announcement of board decisions and related meeting notices. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not financial data or full reports.
2016-12-30 Chinese
关于签署天津昂赛细胞基因工程有限公司《股权转让协议》之变更协议书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change to a previously disclosed equity transfer agreement between subsidiaries and related parties. It details the modification of approval conditions from a shareholders' meeting to a board meeting. The document is short (715 characters) and serves as a formal public notice of this change, not a full financial report or detailed analysis. It does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about a corporate transaction update, fitting best under Regulatory Filings (RNS).
2016-12-27 Chinese
第八届董事会第六十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details decisions made by the board regarding a subsidiary's equity transfer and a loan application. The content focuses on board decisions and authorizations, not on financial results, audit opinions, or regulatory certifications. There is no indication of it being a full annual or interim report, earnings release, or other financial report. The document is clearly about board-level decisions and management actions, fitting the category of Board/Management Information (MANG). The document length is short and contains specific board resolutions, confirming it is not a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2016-12-26 Chinese
独立董事关于子公司协和干细胞基因工程有限公司转让天津昂赛细胞基因工程有限公司38%股权的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a transaction involving the transfer of a subsidiary's equity stake. It references governance rules and confirms the legality and fairness of the transaction. It is not a full financial report, audit, or earnings release, nor is it a regulatory announcement or voting result. The content aligns with a Board/Management Information filing, as it concerns board-level decisions and opinions on corporate actions.
2016-12-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.